| Literature DB >> 30407655 |
Lilla Makszin1,2, Péter Kustán3, Balázs Szirmay3, Csilla Páger1,2, Emerencia Mező1,2, Krisztina I Kalács3,2, Vera Pászthy3, Erzsébet Györgyi3, Ferenc Kilár1,2, Andrea Ludány3, Tamás Kőszegi3,2.
Abstract
Perchloric acid (PCA) precipitation is a well-known method for the separation of heavily glycosylated proteins and for reducing the masking effect of major serum proteins. The aim of this study is to characterize PCA-soluble serum proteins in healthy individuals and in patients with systemic inflammatory diseases, such as Crohn's disease and sepsis. A PCA precipitation protocol was prepared and adapted to the analytical methods. After PCA treatment of the serum, the soluble proteins in the supernatant were analyzed by SDS-PAGE and by microchip gel electrophoresis (MGE). Characteristic changes of the electrophoretic patterns of the PCA-soluble fractions were observed. Four characteristic bands (at ∼11, ∼65, ∼85, and ∼120 kDa) with varying intensity were detected by MGE. The proportion of the ∼65, ∼85, and ∼120 kDa bands were significantly higher in systemic inflammatory conditions than in healthy individuals (p < 0.001), and characteristic patterns were observed in patients with acute inflammation. The marked differences in the acid-soluble protein patterns, which were observed in patients with ongoing systemic inflammation, might be a good indicator of inflammation. The MGE analysis is a fast screening and quantification method for the detection of characteristic changes among acid-soluble serum proteins.Entities:
Keywords: Acid-soluble serum proteins; Inflammation; Microchip gel electrophoresis; Perchloric acid precipitation; Systemic inflammatory diseases
Mesh:
Substances:
Year: 2018 PMID: 30407655 PMCID: PMC6587799 DOI: 10.1002/elps.201800378
Source DB: PubMed Journal: Electrophoresis ISSN: 0173-0835 Impact factor: 3.535
Patients’ parameters (demographic data and routine serum tests)
| Controls ( | Nonactive CD patients ( | Active CD patients ( | Septic patients ( |
| |
|---|---|---|---|---|---|
| Males, | 9 (36.0) | 18 (52.9) | 9 (32.1) | 21 (37.5) | – |
| Age (years) | 29 ± 16 | 26 ± 17 | 26 ± 16 | 67 ± 10 | <0.001 |
| Serum TP (g/L) | 71 (68–74) | 73 (69–77) | 69 (65–73) | 47 (42–51) | <0.001 |
| WBC count (G/L) | 6.4 (4.9–7.7) | 6.9 (6.0–8.9) | 8.9 (6.5–12.3) | 12.7 (8.9–17.8) | <0.001 |
| hs‐CRP (mg/L) | 0.5 (0.2–1.8) | 2.7 (0.9–6.1) | 21.9 (7.1–71.5) | 171.4 (91.9–247.4) | <0.001 |
| Orosomucoid (g/L) | 0.8 (0.7–0.8) | 1.0 (0.8–1.3) | 1.7 (1.2–2.6) | 1.8 (1.4–2.0) | <0.001 |
Medians (interquartiles) are presented except for age: mean ± SD.
TP, total protein; WBC, white blood cell; hs‐CRP, high sensitivity C‐reactive protein; CD, Crohn's disease; Kruskal‐Wallis test with post hoc analysis was used to compare groups. Superscript lowercase letters indicate the significance level of post hoc analysis.
p < 0.01 compared to controls.
p < 0.01 compared to nonactive CD.
p < 0.01 compared to active CD.
MGE protein profiles of PCA‐soluble components (percent (%) of total AUC)
| Controls ( | Nonactive CD patients ( | Active CD patients ( | Septic patients ( |
| |
|---|---|---|---|---|---|
| TP (g/L) | 1.2 (1.0–1.5) | 1.7 (1.4–2.1) | 2.9 (2.2–3.7) | 4.8 (3.9–6.0) | <0.001 |
| ∼11 kDa | 12.2 (7.2–23.8) | 12.1 (9.5–17.2) | 4.4 (2.9–9.0) | 1.2 (0.6–2.1) | <0.001 |
| ∼65 kDa | 5.5 (3.3–10.3) | 7.2 (5.3–11.1) | 10.8 (6.5–18.5) | 14.8 (9.2–19.3) | <0.001 |
| ∼85 kDa | 1.7 (1.2–2.9) | 3.1 (2.5–5.8) | 11.7 (8.2–17.5) | 24.4 (16.2–35.5) | <0.001 |
| ∼120 kDa | 72.3 (62.6–78.3) | 70.2 (64.8–76.2) | 62.8 (56.8–76.5) | 51.5 (41.1–65.8) | <0.001 |
Medians (interquartiles) are presented.
PCA, perchloric acid; TP, total protein; CD, Crohn's disease; Kruskal‐Wallis test with post hoc analysis was used to compare groups. Supersript lowercase letters indicate the significance of post hoc analysis.
p < 0.01 when compared to controls.
p < 0.01 when compared to nonactive CD.
p < 0.01 when compared to active CD patients.
Figure 1SDS‐PAGE gel images with silver staining of PCA‐soluble proteins. (A) control (C1–3), (B) nonactive Crohn's disease (NA1–3), (C) active CD (A1–3), and (D) sepsis (S1‐3). The SDS‐PAGE was run at 190V for 45 min; 10 μL sample was loaded.
M, molecular mass marker.
Figure 2MGE electrophoretic profiles and gel‐like images of PCA‐soluble proteins in healthy controls (C1–3). Experimental conditions of the electrophoresis with the HSP 250 Protein Chip are described in the Materials and methods. The total protein concentration applied in the chip well was roughly 0.1 μg/μL.
Figure 3MGE electrophoretic profiles and gel‐like images of PCA‐soluble proteins in patients with nonactive Crohn's disease (NA1–3). The experimental conditions were the same as in Fig. 2. The total protein concentration applied in the chip well was roughly 0.2 μg/μL.
Figure 4MGE electrophoretic profiles and gel‐like images of PCA‐soluble proteins in patients with active Crohn's disease (A1–3). The experimental conditions were the same as in Fig. 2. The total protein concentration applied in the chip well was roughly 0.3 μg/μL.
Figure 5MGE electrophoretic profiles and gel‐like images of PCA‐soluble proteins in septic patients (S1–3). The experimental conditions were the same as in Fig. 2. The total protein concentration applied in the chip well was roughly 0.5 μg/μL.